Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00815945
Other study ID # AGO-GYN 7
Secondary ID
Status Completed
Phase Phase 2
First received December 30, 2008
Last updated February 13, 2017
Start date June 2008
Est. completion date January 2012

Study information

Verified date March 2014
Source AGO Study Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Uterine sarcomas account for less than 5% of all carcinomas of the uterine corpus. The prognosis of these patients is extremely limited. Recurrence rates of 50-60% are reported even for early-stage disease (FIGO I/II). Median overall survival is below 12 months in patients with advanced or metastatic disease.

Ovarian carcinosarcoma is extremely rare among ovarian malignancies (< 2%). That is why there is insufficient data as a basis for establishing a gold standard. As a result, these cases tend to be treated in the same way as uterine sarcomas or epithelial ovarian malignancies in clinical practice.

On the basis of data published to date on the treatment of mixed mesenchymal-epithelial tumors, it is clear that the treatments commonly used to date have limited activity while producing clinically relevant toxicity. The regimes verified so far (Cisplatin / Ifosfamide, Ifosfamide/Paclitaxel and Gemcitabine/Docetaxel) exhibit a considerable side effect spectrum and are only rarely feasible on clinical everyday life conditions, so e. g. the rate of withdrawals due to toxicity was in a study collective of selected females treated with the last combination at 40 %. The physician has to check in every individual case if one of the above mentioned combinations is feasible. The search for alternative effective and better tolerated treatment options is essential. The toxicity data on the carboplatin-PLD combination are known, and efficacy has been identified in small cohorts.

The objective of this study is to explore the efficacy of combination PLD-carboplatin treatment in a larger patient population.


Description:

This study in patients with mesenchymal or mixed epithelial mesenchymal tumors of the ovary or uterus is designed as a prospective single-arm, open - label, multicenter phase II study to evaluate the efficacy of PegLiposomal Doxorubicin and Carboplatin combination chemotherapy.

40 patients will be recruited to receive PegLiposomal Doxorubicin (PLD) in a continuous i. v. infusion of at least 60 minutes at a dose of 40 mg/m2 on Day 1, followed by a 30-minute i. v. carboplatin infusion according to AUC 6 (formula devised by Calvert et al).

Patients will get outpatients treatment. At screening the patients' eligibility will be assessed, their baseline and demographic characteristics obtained, and baseline values for the effect variables collected. Patients with measurable lesions, non-measurable lesions or histological documentation will be included into this trial. Measurable lesion and non-measurable lesions will be documented by x-ray, ultrasound, computed tomography or MRI.

The patients' safety will be monitored during therapy until recovery of toxicities.

In patients with measurable lesions at baseline, the (post)-treatment values for effect according to the RECIST criteria will be collected as shown in table 6. CR, PR and SD have to be confirmed by a repeat measurement after an interval of at least four weeks.

Follow-up is scheduled every three months during the first two years after the end of treatment.

As from year 3 the follow-up takes place outside the study in the context of general aftercare.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date January 2012
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically documented mesenchymal or mixed epithelial-mesenchymal tumor of the ovary or uterus

- Patients with a primary diagnosis of FIGO I-IV uterine carcinosarcoma and optimum debulking (postoperative residual tumor < 1cm) may be enrolled only if cisplatin-ifosfamide combination therapy is not feasible.

- Patients with metastatic uterine carcinosarcoma may be enrolled only if Ifosfamide/Paclitaxel combination therapy is not feasible.

- Patients with metastatic leiomyosarcoma may be enrolled only if gemcitabine-docetaxel combination therapy is not feasible.

- Measurable (target lesion) tumor, evaluable (non-target lesion) tumor or histological documentation

- No more than one prior chemotherapy. Any prior platinum or anthracycline- containing chemotherapy must have been completed more than 6 months previously

- Prior radiotherapy = 25% of the hematopoietic system is allowed provided it took place more than 6 weeks before recruitment

- Patients are allowed to have received prior anticancer hormone therapy or specific immunotherapy. Patients must have completed these therapies at least three weeks before recruitment to the study

- All women with a theoretical possibility of pregnancy must produce a negative pregnancy test (serum or urinary) within seven days before starting treatment

- General health of 0 - 2 on the ECOG score

- At least 18 years of age

- Estimated life expectancy above 12 weeks

- At least 3 weeks since major surgery

- Appropriate hematologic, renal and hepatic function in accordance with the following definitions:

- Absolute neutrophil count (ANC) = 1.5 × 109 /l

- Platelets = 100 × 10 9/l

- Total bilirubin = 1.25 times upper limit of normal

- Estimated GFR = 50 ml/min

- LVEF > 50 %

- Informed consent must be obtained from all patients.

Exclusion Criteria:

- More than one prior chemotherapy (or radiochemotherapy)

- Active infection or other serious medical impairment liable to affect the patient's ability to receive treatment according to protocol.

- Administration of other chemotherapy drugs or other anticancer hormone treatments during the study.

- History of clinically manifest atrial or ventricular arrhythmia (> LOWN II) and congestive heart failure, even if controlled by drugs (NYHA class > II). Documented myocardial infarction within 6 months before study enrollment.

- Pregnant or breastfeeding women, or women not practicing appropriate birth control methods

- Participation in another study using experimental drugs within the last 30 days

- Any other conditions or therapies which the physician believes might put the patient at risk or impair the study objective.

- Known hypersensitivity to carboplatin or pegylated liposomal doxorubicin

Study Design


Intervention

Drug:
PegLiposomal Doxorubicin
PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
Carboplatin
Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months

Locations

Country Name City State
Germany Charité, Campus Virchow Klinikum, Frauenklinik Berlin
Germany Malteser Krankenhaus, Gynäkologie und Geburtshilfe Bonn
Germany Klinikum Bremen-Mitte gGmbH, Frauenklinik Bremen
Germany Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Dresden
Germany Evangelisches Krankenhaus Düsseldorf, Frauenklinik Duesseldorf
Germany Universitätsklinikum Essen, Frauenklinik Essen
Germany Klinikum der J. W. Goethe-Universität, Klinik für Gynäkologie und Geburtshilfe Frankfurt
Germany University Hospital Hamburg-Eppendorf Hamburg
Germany Gynäkologisch-onkologische Praxis Hannover
Germany St. Vincentius Kliniken AG, Frauenklinik Karlsruhe
Germany Universitätsklinikum Giessen und Marburg GmbH, Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie Marburg
Germany Klinikum Großhadern, Frauenklinik München
Germany Universitätsklinikum Tübingen, Frauenklinik Tübingen
Germany Universitätsklinikum Ulm, Universitätsfrauenklinik Ulm
Germany Dr. Horst Schmidt Kliniken GmbH, Klinik für Gynäkologie und gynäkologische Onkologie Wiesbaden

Sponsors (2)

Lead Sponsor Collaborator
AGO Study Group MSD SHARP & DOHME GmbH (formerly Essex Pharma GmbH)

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Anticancer activity in terms of progression-free survival time (PFS) every 3 months
Secondary Tolerability, i.e. type, frequency, severity and duration of adverse reactions (CTCAE,Version 3.0) until recovery of toxicities
Secondary Anticancer activity in patients with measurable or evaluable disease in terms of response rates (CR, PR, SD, PD) according to RECIST criteria six months
Secondary Overall survival 30 months
Secondary Correlation of tumor marker CA-125 with imaging methods six months
See also
  Status Clinical Trial Phase
Recruiting NCT04535271 - Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma Phase 2
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT06088290 - Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma Phase 2/Phase 3
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Terminated NCT02940041 - Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
Completed NCT01442662 - Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine Phase 2
Completed NCT00062868 - LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Phase 1
Recruiting NCT04214457 - Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
Active, not recruiting NCT04420975 - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Phase 1
Terminated NCT04099277 - A Study of LY3435151 in Participants With Solid Tumors Phase 1
Not yet recruiting NCT05548179 - Exploring Clinical Trial Experiences of People With Leiomyosarcoma
Recruiting NCT02983539 - Detection of Circulating Tumor Cells in Patients With Sarcomas
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Active, not recruiting NCT04624178 - A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Phase 2
Terminated NCT03959033 - Patient Reported Outcome Measures (PROMs) With Trabectedin
Recruiting NCT02275286 - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Phase 1/Phase 2
Active, not recruiting NCT01956084 - Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma Phase 1
Completed NCT01426633 - Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas Phase 1
Completed NCT00400569 - Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT05080790 - Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma Phase 2